Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Effects on Functional Neuroanatomy in TRD
NCT04205890Phase 1Withdrawn
- Sponsor
- Neurological Associates of West Los Angeles
- Start
- May 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketamine in major depressive disorder (MDD), sponsored by Neurological Associates of West Los Angeles. Primary endpoints: Functional Magnetic Resonance Imaging T1-weighted structural imaging at 2 days, Arterial Spin Labeling at 2 days and 1 more. Planned start May 2020; status: withdrawn.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04205890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205890.